PrE1005
PrE1005 asks whether replacing daratumumab with belantamab in initial combination treatment benefits newly diagnosed myeloma patients not undergoing upfront transplantation. A physician described in the source as a principal investigator encourages trial participation, with eligibility remaining a qualification. The physician welcomes the efficacy rationale and dosing approach but presents reduced ocular toxicity as an expectation. In that account, MRD improvement and relevance to high-risk disease remain questions to be tested.
- NCT07285239 ↗
- v1.0.0 · edition 1
- updated Oct 29, 2026
- Focused
5 findings, and what sits behind each
01. Acknowledged activity does not resolve disagreement over a frontline role
6 statements · 4 passages · 1 sources · 2 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Safety and tolerability.
02. The investigator's efficacy expectation rests on earlier-setting evidence and mechanistic differentiation
8 statements · 3 passages · 1 sources · 1 named voices
Counterview: none recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
Draws on: The comparison, Population and setting, Design and conduct.
03. Scheduling is presented as a tolerability advantage, but reduced ocular harm remains an expectation
8 statements · 5 passages · 3 sources · 3 named voices
Counterview: recorded · Limitations recorded: 4. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints, Population and setting, The comparison.
04. MRD improvement and high-risk relevance are questions to be tested, not demonstrated benefits
3 statements · 3 passages · 1 sources · 1 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Primary endpoint: MRD Negative Status, Population and setting, Primary endpoint: Progression-Free Survival (PFS), Secondary endpoints, Design and conduct.
05. Enrollment flexibility is an explicit research-access message, with eligibility qualifications
6 statements · 3 passages · 1 sources · 1 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting, The comparison, Safety and tolerability, Design and conduct.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 5
Acknowledged activity does not resolve disagreement over a frontline role
- statements
- 6
- passages
- 4
- sources
- 1
- named voices
- 2
What the statements areViews 6Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0How passages are usedSupporting a statement 6Giving context 0Recorded with the finding- Counterview: recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 1 post or article
Draws on: Safety and tolerability.
In the full report: the interpretation in full, all 6 statements cited to source and date, and the 1 source linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full PrE1005 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
Under what access, ocular-risk and alternative-treatment conditions would a belantamab quadruplet offer an acceptable frontline trade-off?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 25HCP commentary sources screened
- 3sources cited by verified HCP statements
- 3found in screened sources
- 3voices cited in the report
- 3cited voices matched to verified clinician profiles
Also in the sources: 1 organizational or shared account, not counted as people.
- 28verified statements, each linked to its source
- 26of them from speakers with a confirmed clinical role
- 5findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 28 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 28 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 3 | Counts free |
| Speaker attribution for cited voices | 3 | Paid |
Trial aspects
11 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: MRD Negative Status | 2 | 1 |
| Primary endpoint: Progression-Free Survival (PFS) | 1 | 1 |
| Secondary endpoints | 5 | 1 |
| Population and setting | 6 | 1 |
| The comparison | 5 | 1 |
| Safety and tolerability | 8 | 3 |
| Design and conduct | 3 | 1 |
| DREAMM-9 exchange: access, alternatives and a frontline role | 7 | 2 |
| Earlier-study evidence and mechanistic rationale | 8 | 2 |
| Enrollment timing, future transplantation and study-team support | 5 | 1 |
| Baseline preparation for sequencing-based MRD assessment | 1 | 1 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 24 | 2 | |
| YouTube | 1 | 1 |
max 18 / quarter
- Screened window
- May 29, 2026 → Oct 27, 2026
- Cited window
- May 29, 2026 → Oct 7, 2026
- Retrieved
- Oct 29, 2026
The trial
from ClinicalTrials.gov- Title
- Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Registry
- NCT07285239
- Study IDs
- PrE1005 · GSK 300057 (GlaxoSmithKline)
- Sponsor
- PrECOG, LLC.
- Collaborators
- GlaxoSmithKline
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 500 estimated
- Start
- 2026-09 estimated
- Primary completion
- 2031-11 estimated
- Primary endpoint
- MRD Negative Status
- Interventions
- 5 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The views summarized here come from a small set of discussions and cannot establish the prevalence of any opinion among HCPs.
- Some additional posts were not fully assessed, and unnamed trial references or different wording may have been missed.
- No protocol or publication reporting outcomes for this exact trial was available for this edition; investigator expectations and earlier-study observations cannot be treated as PrE1005 results.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Approved indications and local access to the discussed alternatives were not comprehensively assessed.
- The LMIC comparison contains an ambiguous word, and the rare circumstances in which a speaker might accept frontline belantamab are unspecified.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. PrE1005 (NCT07285239): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/pre1005-nct07285239
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "PrE1005" (NCT07285239), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "pre1005-07285239". If you cannot make requests, read https://www.erudio.com/reports/pre1005-nct07285239.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07285239", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07285239 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/pre1005-nct07285239.json
curl https://www.erudio.com/reports/pre1005-nct07285239.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "pre1005-07285239" })release 210213f5b6b1ecb2c5cb10d521b5aaffa43d1e5f917b761763829f443c8d6f47